Novavax Gets the EU Green Light – and the Spotlights in Brussels
In a move that’s giving vaccine distributors a new reason to celebrate, the European Commission just approved Novavax and its protein‑based Covid‑19 jab for use across the EU.
Key highlights
- EU’s vaccine buffet now has a fourth flavour: Alongside mRNA marvels, there’s the classic, protein‑based Novavax.
- Ursula von der Leyen’s tweet: “With five approved vaccines, the EU has a varied portfolio…” – a clear nod to the diversity of approaches.
- EMA cheers: The human medicines committee confirmed the data was “robust” and met EU safety, efficacy, and quality standards.
- Delivery schedule: Countries that have already bought the shots will start receiving them in January.
- Effectiveness: Two big studies back an ~90% efficacy rate, though data on the new Omicron sub‑variants is still coming in.
- Market buzz: Novavax shares jumped about 10% in U.S. pre‑market trading after the EMA verdict.
- Global angle: The vaccine cleared Indonesia last month and is waiting for Japan/Takeda’s go‑ahead.
Why the rush?
The EU is on a roll, pushing reviews for all shots in the face of surging Omicron cases, especially as communities gear up for the holiday season.
- Previous favourites, like Pfizer‑BioNTech, Moderna, AstraZeneca, and J.&J., were already in the EU’s armory.
- Novavax’s recent delay was due to manufacturing hiccups; they’re hoping to resolve that and hit the U.S. market by year‑end.
- It took the EMA a little longer than expected, starting a rolling review back in February.
- Though the EU contract (for up to 200 million doses) was only signed in August, the delivery will keep rolling through 2025.
Bottom line
Thanks to the EU’s approval, the continental spread of Novavax will keep the vaccine train chugging, giving healthcare workers another tool in the fight against Covid‑19 – especially when the next wave looks as mischievous as ever.
